Histamine dose-response curves in asthma: relevance of the distinction between PC₂₀ and reactivity in characterising clinical state

A BEAUPRÉ, JL MALO

From the Department of Chest Medicine, Hôpital du Sacré-Coeur, Montreal, Canada

ABSTRACT The aim of the present study was to determine if the measurement of the slope of the histamine dose-response curve (bronchial reactivity) could provide useful information on the clinical state of asthma. Fifteen adult asthmatic subjects were studied twice at an interval of one year. Their clinical state was assessed by comparing their respiratory symptoms, need for medication, and FEV₁ on both visits. Histamine inhalation challenges were carried out in a similar manner both times using a standardised procedure. PC₂₀FEV₁ (the histamine concentration causing a 20% fall of FEV₁) and reactivity were obtained from the dose-response curves. As others have shown, we found that PC₂₀FEV₁ reflects clinical state. Indeed, changes of PC₂₀FEV₁ greater than a single two-fold dilution of histamine were shown by five of six patients who were not in a steady clinical state, and by none of the nine patients who were. Changes of PC₂₀FEV₁ were significantly ($p < 0.005$) more important in those who were not in a steady state in comparison with those who were. The reproducibility of reactivity was slightly better in those individuals who were in a steady clinical state as compared with those who were not. Nevertheless, changes in reactivity did not allow significant differentiation between the two groups of subjects. We conclude that PC₂₀FEV₁ is a more helpful index than reactivity in characterising the clinical state of asthmatics.

Bronchial reactions to inhaled non-allergic agents such as histamine and acetylcholine derivatives are characterised mainly by the dose required to produce a fixed change in a functional measurement. When FEV₁ is the functional index used, a 20% change is generally judged as significant in reflecting bronchial hyperexcitability.¹ The provocative concentration producing a 20% change in FEV₁ (PC₂₀FEV₁) has thus been proposed to quantify the reaction.²

Orehek and Gayraud³ have suggested that inhalation dose-response curves should be studied in a pharmacological manner in which distinction is made between sensitivity (the dose at which reaction is initiated) and reactivity (the slope of the dose-response curve beyond this point). The relevance of making this distinction derives from the fact that asthmatics are distinguished from normal individuals by reactivity more than by sensitivity.⁴

It is not known whether reactivity is related to the clinical state of asthma. We therefore decided to study PC₂₀FEV₁ and reactivity in asthmatic subjects

who either were in a steady clinical state or showed alterations in their condition.

Methods

Fifteen adult asthmatic subjects were studied (nine men and six women) whose age ranged from 18 to 52 years (mean = 33.7; SD = 12.3, table). All subjects met the criteria for the definition of asthma proposed by the American Thoracic Society.⁵ In addition, all subjects had previously shown, either spontaneously or after inhaled bronchodilator, a variation in FEV₁ of 20% or more. Skin prick tests were done with a routine battery of 15 common inhaled antigens extracts. Atopy was considered to be present whenever a patient had two or more immediate positive skin reactions. Eleven subjects were found to be atopic.

On their first visit, all these patients were in a clinical steady state and 11 of them had been included in another study.⁶ At that time, they reported no exacerbation of asthma in the previous two months and no recent respiratory infection. On the

Address for reprint requests: Dr JL Malo, 5400 Gouin West, Montreal, Canada H4J 1C5.

Table Summary of data on patients studied

Number	Age (yr)	Sex	Atopy*	Symptoms		Treatment†		Pred	FEV ₁ (l)		ΔFEV ₁ ‡
				Visit 2	Visit 1	Visit 1	Visit 2		Obs	Obs	
				Diurnal	Night				Visit 1	Visit 2	
1	44	F	—	↓	—	1	0	2.2	1.35	1.45	+7
2	44	M	+	Same	—	2	1	3.5	2.70	2.70	0
3	18	F	+	↓	—	2	1	2.9	2.60	2.90	+11
4	52	M	—	Same	—	3+	3+	3.6	2.70	2.70	0
5	30	M	+	Same	—	2	1	4.0	3.70	3.65	-1
6	44	M	+	Same	—	1	1	3.9	2.90	2.85	-2
7	17	F	+	Same	—	2	3	3.2	3.75	4.00	+6
8	18	M	+	↑	—	1	1	3.8	4.50	3.60	-20
9	37	F	—	↑	+	1	2	2.4	3.10	2.90	-6
10	45	M	+	↓	—	4	4	3.9	1.65	3.05	+46
11	50	M	—	Same	—	3+	3+	3.2	3.10	3.30	+6
12	25	F	+	Same	—	1	1	2.9	2.10	2.10	+5
13	30	F	+	↓	—	3+	3+	2.9	2.50	2.65	+6
14	32	F	+	Same	—	3	3	2.5	2.40	1.80	-25
15	20	F	+	↓	—	4	3	3.1	2.20	2.50	+12

*Atopy: present if two or more immediate position skin prick reaction to a routine battery of 15 common inhaled antigens extracts.

†Treatment: 0: none; 1: beta-adrenergic stimulants or phosphodiesterase inhibitors PRN; 2: beta-adrenergic stimulants or phosphodiesterase inhibitors or sodium cromoglycate continuously; 3: aerosolised beclomethasone at 400 µg daily continuously; 3+: aerosolised beclomethasone at 800 µg daily continuously; 4: oral corticosteroids.

‡Assessed by: $\frac{\text{FEV}_1 \text{ visit 2} - \text{FEV}_1 \text{ visit 1}}{\text{FEV}_1 \text{ visit 1}} \times 100$

second visit, one year (± 1 month) after the initial assessment, each of the patients was required to answer a respiratory questionnaire as regards diurnal symptoms, nocturnal waking caused by asthma, and recent respiratory infections. Special attention was paid to the two latter items, since the presence of nocturnal symptoms^{7,8} has been shown to reflect an unsteady clinical state. It has also been shown that recent respiratory infections alter non-specific bronchial hyperexcitability.⁹ Significant changes in the clinical state between the two visits were considered whenever at least two of the three following criteria were met: change in the respiratory questionnaire, change in drug requirement, and change of 10% or more of the initial FEV₁. Drug requirement is indeed related to the level of airway hyperexcitability.² Changes in FEV₁ of 10% or more exceed the percentage of reproducibility of the test and have been considered by others¹⁰ as reflecting an unsteady clinical state.

On both visits, medications were withheld for the interval suggested by the special committee appointed by the American Academy of Allergy.¹ The two assessments were carried out at the same time of the day. Informed consent was given by each subject and the study was accepted by a medical ethics committee.

On both occasions, the subjects were asked to perform a forced expiratory manoeuvre to assess their initial FEV₁. The histamine inhalation challenge was performed in the manner suggested by Chai *et al.*¹ using the dosimeter coupled with a no 646 De Vilbiss nebuliser. The same diluent and histamine phosphate concentrations were used each

time. Forced expiratory manoeuvres were carried out twice at each of 30, 90, and 180 seconds after the end of each nebulisation. In order to assess bronchial reactivity, a fall of FEV₁ to approximately 35% of the initial value was obtained, at which concentration the test was stopped. The subjects were then given two inhalations of salbutamol in aerosol and in all cases the FEV₁ was back to the initial values within 10 minutes.

The percentage fall in FEV₁ was calculated from the formula suggested by Cockcroft *et al.*²:

$$\% \text{ change} = 1 - \frac{\text{lowest FEV}_1 \text{ post histamine}}{\text{lowest FEV}_1 \text{ post diluent}} \times 100$$

The dose of histamine producing a 20% change in FEV₁ was calculated from the individual semi-logarithmic dose-response curve (PC₂₀FEV₁). In order to assess reactivity, the slope of the dose-response curve was measured as follows. The histamine concentration expressed logarithmically on the abscissa was related to the percentage change in FEV₁ on the ordinate using linear regression analysis. Only those points sustaining a progressive and steady decline in FEV₁ were included. The analysis was carried out on points inclusive between the last one plotted and backwards to the point where a change in FEV₁ greater than two standard deviations of the six post-diluent values was noticed. Three to four points were included for each curve. For each subject and at each visit, these points were within the same range of change in FEV₁, the maximal obtained fall in FEV₁ being close ($\pm 10\%$) at each test. Correlation coefficients of dose-response curves were calculated by the method of least squares. The

level of statistical significance required for a curve to be retained for analysis was a probability of 0.05. Those curves drawn from the FEV₁ values assessed at either 30, or 90, or 180 seconds after the end of the nebulisation, and which bore the highest statistically significant correlation coefficients, were selected to analyse reactivity. The coefficient *m* from the formula $y = mx + b$ was used to indicate reactivity.

Student's unpaired *t* test was used to compare the changes in PC₂₀FEV₁ and in reactivity between the group judged to be in a steady clinical state and that judged to be in an unsteady one.

Forced expiratory manoeuvres were carried out on a Vitalograph spirometer. Reference values for FEV₁ were taken from Goldman and Becklake.¹¹

Results

The table gives the anthropometric, clinical and physiological data for each subject. Six subjects (1, 3, 8, 9, 10, and 15) were judged not to be in a clinical steady state since they fulfilled at least two of the following criteria: changes in symptoms either

during the day or at night, change in drug requirement, and change in FEV₁ of 10% or more. One patient (9) reported recent respiratory infections causing night symptoms.

Figure 1 shows the individual results for PC₂₀FEV₁. In the nine subjects who did not experience clinical changes from one visit to the other, PC₂₀FEV₁ did not change by more than a single two-fold dilution of histamine, a value which is considered by others to be significant.^{12,13} In this group of patients, the correlation coefficient *r* of the PC₂₀FEV₁ values for the two visits was 0.92. In contrast, five of the six subjects who were judged not to be in a clinical steady state showed significant changes in PC₂₀FEV₁. Changes in PC₂₀FEV₁ were significantly more pronounced ($p < 0.005$) in the group of subjects in an unsteady state in comparison with the group who showed no clinical changes. PC₂₀FEV₁ was also significantly related to the initial FEV₁ expressed in percentage of the predicted reference value ($r = 0.42$, $p < 0.02$).

Individual results for reactivity are plotted on fig 2 where distinction is made between subjects who changed their clinical state and subjects who did not.

Fig 1 Individual results on logarithmic scales of PC₂₀FEV₁ on each visit—
● = patients in a clinical steady state;
□ = patients whose clinical state improved on the second visit;
Δ = patients whose clinical state worsened on the second visit.
The non-interrupted line is the line of identity. The area between the two dashed lines represents the region of single twofold dilution difference.

Fig 2 Individual results of reactivity (slope m of the dose-response curve $y = mx + c$). There was no significant difference between changes in patients who did not change their clinical state (●) and those in patients who worsened (▲) or improved (□).

The reproducibility of reactivity was slightly better in those individuals who were in a steady clinical state as compared with those who were not ($r = 0.85$ and 0.73 respectively). Nevertheless, changes in reactivity were statistically not significantly different for the two groups of subjects.

Dose-response curves of two subjects in a steady and unsteady clinical states are drawn on fig 3.

Discussion

Reviving Tiffeneau's suggestion that inhalation dose-response curves should be analysed in a true biological manner,¹⁴ Orehek and Gayraud suggested distinguishing between the threshold dose, which they called sensitivity, and the slope of the reaction beyond this point, which they called reactivity.³ The same workers showed that asthmatics differ from normal subjects more in terms of reactivity than of sensitivity.⁴ These authors have also demonstrated that such distinction between sensitivity and reactivity can be accomplished by using FEV_1 as the physiological index reflecting the reaction.¹⁵

We asked ourselves if this distinction might provide clinically useful information. Our study shows that changes in $PC_{20}FEV_1$ from one visit to the other differentiate individuals who are in a clinical steady state from those who are not. Others have also found that $PC_{20}FEV_1$ or related indices reflect clinical state and the need for medication.^{2,16} Changes in $PC_{20}FEV_1$, like those occurring in the pollen season¹⁷ or after an antigen challenge,¹⁸ have also been demonstrated in patients who were in an

Fig 3 Dose-response curves in two subjects. Patient 10 in a steady clinical state (left panel) showed no significant changes of $PC_{20}FEV_1$ and reactivity. Patient 11 in an unsteady clinical state (right panel) demonstrated a marked change in $PC_{20}FEV_1$ but no significant change in reactivity. (●) = first visit; (○) = second visit.

unsteady clinical state. There was a significant relationship between $PC_{20}FEV_1$ and the initial FEV_1 ($r = 0.42$, $p < 0.02$) and this is also in keeping with previous findings^{2 16 19 20} which relate airways hyperexcitability with the initial airways obstruction. In a previous report,⁶ the correlation coefficient between $PC_{20}FEV_1$ assessed with the Dosimeter and the initial FEV_1 (expressed in percentage of the predicted value) was 0.36. This result is slightly less than the correlation coefficient of 0.42 found in the present study. This discrepancy may be explained by the fact that the two investigations did not include exactly the same subjects (only 11 of the total of 24 patients were common to the two studies).

One of the six patients who experienced changes in symptoms and need for medication demonstrated changes in FEV_1 which were less than 10% from one visit to the other. This patient (9) reported night symptoms and exhibited alterations in $PC_{20}FEV_1$. As shown by others,⁷ asthmatics may well show significant airways obstruction only at night. In these individuals, the assessment of $PC_{20}FEV_1$ may better reflect the unsteady clinical state than a single measurement of FEV_1 during the day.

We show that reactivity does not appear to parallel the changes in the clinical state of our patients. Changes in reactivity were indeed not significantly different in the two groups of patients, whether they were in a steady clinical state or not. It was Orehek's opinion⁴ that a valid experimental model of asthma should take account of increase in sensitivity as well as in reactivity. The conclusion of our study is that reactivity does not reflect the clinical state of asthma as defined by the clinical symptoms, drug requirement, and FEV_1 .

Many features of the analysis of the non-specific inhalation dose-response curves have yet to be examined. First is the method used to calculate the slope of the dose-response curve. Orehek *et al*⁴ did not use logarithmic transformation of the cumulative carbachol doses, and plotted the points on a linear scale. This procedure may tend to exaggerate the slope of the asthmatic subjects who reacted at a lower concentration and to diminish excessively the slope of the normal individuals whose threshold occurred at a higher concentration. Reanalysing their dose-response curves in a semi-logarithmic way, Orehek mentioned that reactivity nevertheless still differentiates asthmatic from normal subjects (personal communication).

The second item for discussion in the analysis of the dose-response curve is the threshold point. Orehek and his colleagues¹⁵ suggested that the threshold should be a change of 15% in FEV_1 when this measurement is used. This threshold point appears to us rather arbitrary. We indeed showed that

linear curves can be drawn by using points below the 15% limit. Fifteen per cent is well above the intrasubject reproducibility of the FEV_1 . We think that for each subject, changes of FEV_1 which were beyond two standard deviations of the six post-diluent measurements should reasonably be included in the individual curve. This opinion has also been expressed by others.²¹ Another point which seems important is the upper limit of changes in FEV_1 which should be included in the dose-response curve. The maximal change in FEV_1 obtained for each subject and at each visit should be similar so that curves are analysed within the same range of changes of FEV_1 .

Although we observed that clinical state as defined in our study by symptomatology, drug requirement, and changes in FEV_1 does not influence reactivity, the influence of other factors such as time of day when the test is performed, previous drug administration, and inhalation of pollutants has yet to be determined.

We would like to thank the patients who kindly agreed to take part in this study, and the Canadian Thoracic Society for financial assistance.

References

- Chai H, Farr RS, Froehlich LA *et al*. Standardization of bronchial inhalation challenge procedures. *J Allergy Clin Immunol* 1975;**56**:323-7.
- Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. *Clin Allergy* 1977;**7**:235-43.
- Orehek J, Gayraud P. Les tests de provocation bronchique non-spécifiques dans l'asthme. *Bull Europ Physiopath resp* 1976;**12**:565-98.
- Orehek J, Gayraud P, Smith AP, Grimaud C, Charpin J. Airway response to carbachol in normal and asthmatic subjects. *Am Rev Respir Dis* 1977;**115**:937-43.
- American Thoracic Society. Chronic bronchitis, asthma and pulmonary emphysema. A statement by the Committee on diagnostic standards for nontuberculous respiratory diseases. *Am Rev Respir Dis* 1962;**85**:762-8.
- Beaupré A, Malo JL. Comparison of the results of two methods of histamine bronchial challenges with the Wright nebulizer and the dosimeter. *Clin Allergy* 1979;**9**:575-83.
- Turner-Warwick M. On observing patterns of airflow obstruction in chronic asthma. *Br J Dis Chest* 1977;**71**:73-86.
- Clark TJH, Hetzel MR. Diurnal variation of asthma. *Br J Dis Chest* 1977;**71**:87-92.
- Empey DW, Laitinen LA, Jacobs L, Gold WM, Nadel JA. Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. *Am Rev Respir Dis* 1976;**113**:131-9.
- Anderton RC, Cuff MT, Frith PA *et al*. Bronchial responsiveness to inhaled histamine and exercise. *J Allergy Clin Immunol* 1979;**63**:315-20.
- Goldman HI, Becklake MR. Respiratory function tests: Normal values at median altitudes and the prediction of normal results. *Am Rev Tuberc* 1959;**79**:457-67.

- ¹² Juniper EF, Frith PA, Dunnett C, Cockcroft DW, Hargreave FE. Reproducibility and comparison of responses to inhaled histamine and methacholine. *Thorax* 1978;**33**:705-10.
- ¹³ Lam S, Wong R, Yeung M. Nonspecific bronchial reactivity in occupational asthma. *J Allergy Clin Immunol* 1979;**63**:28-34.
- ¹⁴ Tiffeneau R, Drutel P. Les aérosols d'acétylcholine dans l'exploration fonctionnelle des poumons. Étude de leurs actions motrice et sensitive. Applications pratiques. *Poumon* 1955;**11**:385-468.
- ¹⁵ Orehek J, Kabondo P, Charpin J, Grimaud C. Mesure spirométrique de la réponse bronchique au carbachol dans l'asthme. *Bull Europ Physiopath Respir* 1978;**14**:493-502.
- ¹⁶ Makino S. Clinical significance of bronchial sensitivity to acetylcholine and histamine in bronchial asthma. *J Allergy* 1966;**38**:127-42.
- ¹⁷ Altounyan REC. Changes in histamine and atropine responsiveness as a guide to diagnosis and evaluation of therapy of obstructive airways disease. In: Pepys J, Frankland AW, eds. *Disodium cromoglycate in allergic airways disease*. Edinburgh and London: Butterworths, 1970:47.
- ¹⁸ Cockcroft DW, Ruffin RE, Dolovich J, Hargreave FE. Allergen-induced increase in non-allergic bronchial reactivity. *Clin Allergy* 1977;**7**:503-13.
- ¹⁹ Oppenheimer EA, Rigatto M, Fletcher CM. Airways obstruction before and after isoprenaline, histamine, and prednisolone in patients with chronic obstructive bronchitis. *Lancet* 1968;**1**:552-7.
- ²⁰ Gayraud P, Orehek J, Charpin J. Tests de provocation bronchique chez les asthmatiques: influence de la valeur fonctionnelle de départ. *Rev Franc Mal Respir* 1976;**4**, suppl 1:51-6.
- ²¹ Habib MP, Paré PD, Engel LA. Variability of airway responses to inhaled histamine in normal subjects. *J Appl Physiol* 1979;**47**:51-8.